Core Insights - The article discusses the fraudulent practices of Nohui Health, revealing that the company engaged in significant sales performance falsification, leading to severe consequences including stock suspension and management turnover [1][2][10] Group 1: Fraudulent Practices - Nohui Health was found to have fabricated sales performance, employing methods such as purchasing fecal samples from sanitation workers and splitting samples among fake testing accounts [2] - The company's top management was aware of and led the fraudulent activities, with only a few executives allowed to attend confidential sales strategy meetings [2][8] - In 2022, Nohui Health's sales team reported a 260% revenue growth, with sales figures soaring from 200 million to 760 million yuan, despite adverse market conditions [7][10] Group 2: Consequences and Reactions - The release of a short-selling report by CapitalWatch triggered a series of events including Deloitte's refusal to sign off on financials, stock suspension, and the resignation of several executives [1][10] - Nohui Health's attempts to manipulate its financial reports in early 2024 led to Deloitte's withdrawal from the audit process, further exacerbating the company's troubles [2][10] - The company is now facing liquidation proceedings, with a court hearing scheduled for November 14, 2023, and over 4,000 individual investors seeking compensation for their losses [13][10] Group 3: Market Impact - Following the short-selling report, Nohui Health's stock price plummeted from a peak of 38.95 HKD to 15.7 HKD, with trading volume surging to over 28 million shares on the day of the report [10][11] - The fraudulent activities have been acknowledged in legal proceedings, with evidence presented that confirms the systematic nature of the sales fraud [10][12] Group 4: Future Outlook - The founders of Nohui Health have initiated a new venture, indicating a potential shift in focus while the original company faces inevitable delisting and liquidation [12][13] - Investors are left in a precarious position, with individual investors unable to recover their investments while awaiting the outcome of legal investigations [13]
诺辉健康“造假”内幕：找环卫工人买粪便，一份样本多次检测